PRKDC and breast cancer: These results suggest that ZNF257KD-mediated resistance to PARPis involves the DNA-PKcs pathway, which may represent a therapeutic target for overcoming PARPi resistance in BRCA1mut + ZNF251KD breast cancer cells.